- Email: [email protected]
Vaccine against infectious bovine keratoconjunctivitis containing cyanogen bromide cleavage fragments of pili of a pathogenic strain of Moraxella bovis
Patent Report Recombinant vaccinia virus containing flavi virus genes used in vaccine against flavi virus infections, especially dengue virus Nat. Inst. Health, Betheseda
US 7239 205; 21 March 1989 A new recombinant vaccinia virus contains the complete coding sequence for expression of flavi virus antigenic proteins, for use in a new vaccine. More specifically, a recombinant vaccinia virus containing coding sequences for the capsid (C), membrane (M), and envelope (E) structural proteins and the NSl and NS2a non-structural proteins of dengue virus was produced by inserting a 4 kb BglII fragment of dengue virus type-4 cDNA into the plasmid pSC 11 vaccinia intermediate vector to produce plasmid pDVSN, which was used for transfection of monkey CV-1 cell culture infected with vaccinia virus WR strain. Other recombinants containing C-M-E and NSl-NS2a coding sequences were also produced. In tests on mice, all three recombinants gave protection (96100%) against dengue virus infection, indicating that the E and NSl glycoproteins are separate protective antigens. The new vaccines may be used for the prevention of flavi virus diseases caused by dengue virus, Japanese-B-encephalitis virus, and tick-borne encephalitis virus. 095-89
Recombinant fowl-pox virus strains containing DNA insert encoding heterologous protein, especially for recombinant vaccine production Transgene
Eur. 314 569; 3 May 1989 New recombinant fowl pox virus (FPV) strains are derived from an attenuated FPV strain and contain, in a non-essential part of its genome, a DNA fragment encoding all or part of a heterologous protein and the elements necessary for expression of this protein in cells infected by the recombinant virus. Also claimed are: (1) DNA fragments encoding at least one gene heterologous to FPV under the control of a pox virus promoter, flanked by the 3’ end of open reading frame (ORF) 7 and the 5’ end of ORF 9; (2) plasmids containing the new DNA; (3) eukaryotic cell cultures transfected with recombinant FPV; (4) vaccines containing recombinant FPV; and (5) antibodies to recombinant FPV. Recombinants containing genes encoding virus antigens are useful for vaccinating poultry against Newcastle disease, infectious bronchitis or Marek’s disease, or for the production of vaccines against morbillivirus infections, e.g. measles, Carre’s disease or rinderpest. In an example, vector plasmid pTGl177 (containing a FPV, /?-galactosidase (EC3.2.1.23) fusion protein under the control of a vaccinia virus promoter) was used to transfect fowl embryo cell culture. 096-89
Vaccine for protecting poultry against Escherichia coli septicemia contains Fll-type fimbria, immunogenic section or antibody directed against them Akzo
oxygen saturation of 40%. Fimbriae were released from the bacteria by heating at 65°C for 15min and/or by 15 rounds of Sorval Omnimixer treatment. After filtration, the filtrate was concentrated and iimbriae were precipitated with ammonium sulphate. The vaccine was used to -protect broilers against 097-89 septicemia.
Vaccine against infectious bovine keratoconjunctivitis containing cyanogen bromide cleavage fragments of pili of a pathogenic strain of Moraxelfa bovis Uni. Tennessee
US 4818 528; 4 April 1989 A vaccine against cattle kerat&onjunctivitis is new and comprises a carrier and protein fragments derived from individual pili of a pathogenic strain of Moraxella bovis by cleaving them with cyanogen bromide. Each protein fragment includes at least one antigenic site, exposed during cleavage, which is common to all pathogenic strains of M. bouis. The protein fragments are capable of inducing the production of antibodies reactive to the antigenic site. The antibodies are non-specific for the M. bouis strain from which the protein fragments were derived. The M. bovis strains may be NPTn, EPP-63, IBH-64 or FLA-64. The DNA sequence encoding a common antigenic site may be clbned and expressed in a suitable host for the production of recombinant protein fragments. The cleavage of pilin proteins with cyanogen bromide exposes immunogenic determinants which are immunorecessive on the uncleaved pilus protein but are common to all strains of M. bouis. Cattle are inoculated with the recombinant vaccine to protect them against infection by M. bouis strains. 098-89 Recombinant vaccinia virus encephalitis-lethargica antigen gene cloning and expression; recombinant vaccine preparation Nippon Zohi Pharm.
Japan 1177 780; 10 May 1989 A recombinant vaccinia virus is claimed, containing cDNA for a gene encoding the structural protein of encephalitis-lethargica virus. The recombinant vaccinia virus is useful as a vaccine, and is safe, since it causes no lesions in the central nervous system. In an example, a Hind111 J fragment with the vaccinia virus TK gene was isolated, and plasmid PJl was constructed from plasmid pBR322 connected with the Hind111 J fragment. Plasmid PZ2 was constructed from a subclone. A Sal1 DNA fragment containing the mol.wt 7500 protein promoter was isolated, and used for the construction of plasmid PZ3, with plasmid pBR322. Plasmid PZ3E-8, plasmid pZ3E-10, plasmid PZ3-E12, plasmid PZ4, plasmid PZ4E-8, plasmid PZ4E-10 and plasmid PZ4E-12 were also prepared. The recombinant vaccinia virus was prepared, and the virus antigen was expressed by the recombinant. The recombinant vaccinia virus prepared by recombination with plasmid pZ3E-8 is virus VpZef-8, and others are named in the same manner. 099-89
Eur. 314 224; 3 May 1989 A vaccine for protecting poultry from Escherichia coli septicemia comprises fimbriae of the F-11 type or an immunogenic section of the fimbriae or recombinant organisms (preferably bacteriri) containing genetic material which encodes the production of and optionally the secretion of the timbriae. The vaccine contains as the immunogenic section, an immunogenic fimbriae subunit protein. The vaccine contains l&lOO~g/ dose of fimbriae and preferably also contains an adjuvant and antibodies directed against limbriae of Fll type. Also new is a method for protecting poultry against E. coli septicemia, which comprises administering the new vaccine. In an example, an E. coliF11 limbriaecloneAM1727-pPIL291-13 wascultured for 16 h in brain heart infusion broth at 37°C and pH 7.4 with
New Plasmodium falciparum antigens useful for recombinant vaccine and antibody production and diagnosis Behringwerke
Eur. 315 085; 10 May 1989 The HRPII antigen of Plasmodium falciparum strain SGE2, of specified amino acid composition, and antigenically active fragments are new. Also new are: (1) fusion proteins containing the antigens; (2) DNA and RNA encoding the antigens; (3) vectors and DNA structures encoding the antigens or fusion proteins; (4) host cell containing the DNA or vectors; and (5) antibodies produced against the antigens or fusion proteins. The recombinant antigens are useful for recombinant vaccine production and for malaria diagnosis. 100-81
Vaccine, Vol. 7, December 1989
575
US 7239 205; 21 March 1989 A new recombinant vaccinia virus contains the complete coding sequence for expression of flavi virus antigenic proteins, for use in a new vaccine. More specifically, a recombinant vaccinia virus containing coding sequences for the capsid (C), membrane (M), and envelope (E) structural proteins and the NSl and NS2a non-structural proteins of dengue virus was produced by inserting a 4 kb BglII fragment of dengue virus type-4 cDNA into the plasmid pSC 11 vaccinia intermediate vector to produce plasmid pDVSN, which was used for transfection of monkey CV-1 cell culture infected with vaccinia virus WR strain. Other recombinants containing C-M-E and NSl-NS2a coding sequences were also produced. In tests on mice, all three recombinants gave protection (96100%) against dengue virus infection, indicating that the E and NSl glycoproteins are separate protective antigens. The new vaccines may be used for the prevention of flavi virus diseases caused by dengue virus, Japanese-B-encephalitis virus, and tick-borne encephalitis virus. 095-89
Recombinant fowl-pox virus strains containing DNA insert encoding heterologous protein, especially for recombinant vaccine production Transgene
Eur. 314 569; 3 May 1989 New recombinant fowl pox virus (FPV) strains are derived from an attenuated FPV strain and contain, in a non-essential part of its genome, a DNA fragment encoding all or part of a heterologous protein and the elements necessary for expression of this protein in cells infected by the recombinant virus. Also claimed are: (1) DNA fragments encoding at least one gene heterologous to FPV under the control of a pox virus promoter, flanked by the 3’ end of open reading frame (ORF) 7 and the 5’ end of ORF 9; (2) plasmids containing the new DNA; (3) eukaryotic cell cultures transfected with recombinant FPV; (4) vaccines containing recombinant FPV; and (5) antibodies to recombinant FPV. Recombinants containing genes encoding virus antigens are useful for vaccinating poultry against Newcastle disease, infectious bronchitis or Marek’s disease, or for the production of vaccines against morbillivirus infections, e.g. measles, Carre’s disease or rinderpest. In an example, vector plasmid pTGl177 (containing a FPV, /?-galactosidase (EC3.2.1.23) fusion protein under the control of a vaccinia virus promoter) was used to transfect fowl embryo cell culture. 096-89
Vaccine for protecting poultry against Escherichia coli septicemia contains Fll-type fimbria, immunogenic section or antibody directed against them Akzo
oxygen saturation of 40%. Fimbriae were released from the bacteria by heating at 65°C for 15min and/or by 15 rounds of Sorval Omnimixer treatment. After filtration, the filtrate was concentrated and iimbriae were precipitated with ammonium sulphate. The vaccine was used to -protect broilers against 097-89 septicemia.
Vaccine against infectious bovine keratoconjunctivitis containing cyanogen bromide cleavage fragments of pili of a pathogenic strain of Moraxelfa bovis Uni. Tennessee
US 4818 528; 4 April 1989 A vaccine against cattle kerat&onjunctivitis is new and comprises a carrier and protein fragments derived from individual pili of a pathogenic strain of Moraxella bovis by cleaving them with cyanogen bromide. Each protein fragment includes at least one antigenic site, exposed during cleavage, which is common to all pathogenic strains of M. bouis. The protein fragments are capable of inducing the production of antibodies reactive to the antigenic site. The antibodies are non-specific for the M. bouis strain from which the protein fragments were derived. The M. bovis strains may be NPTn, EPP-63, IBH-64 or FLA-64. The DNA sequence encoding a common antigenic site may be clbned and expressed in a suitable host for the production of recombinant protein fragments. The cleavage of pilin proteins with cyanogen bromide exposes immunogenic determinants which are immunorecessive on the uncleaved pilus protein but are common to all strains of M. bouis. Cattle are inoculated with the recombinant vaccine to protect them against infection by M. bouis strains. 098-89 Recombinant vaccinia virus encephalitis-lethargica antigen gene cloning and expression; recombinant vaccine preparation Nippon Zohi Pharm.
Japan 1177 780; 10 May 1989 A recombinant vaccinia virus is claimed, containing cDNA for a gene encoding the structural protein of encephalitis-lethargica virus. The recombinant vaccinia virus is useful as a vaccine, and is safe, since it causes no lesions in the central nervous system. In an example, a Hind111 J fragment with the vaccinia virus TK gene was isolated, and plasmid PJl was constructed from plasmid pBR322 connected with the Hind111 J fragment. Plasmid PZ2 was constructed from a subclone. A Sal1 DNA fragment containing the mol.wt 7500 protein promoter was isolated, and used for the construction of plasmid PZ3, with plasmid pBR322. Plasmid PZ3E-8, plasmid pZ3E-10, plasmid PZ3-E12, plasmid PZ4, plasmid PZ4E-8, plasmid PZ4E-10 and plasmid PZ4E-12 were also prepared. The recombinant vaccinia virus was prepared, and the virus antigen was expressed by the recombinant. The recombinant vaccinia virus prepared by recombination with plasmid pZ3E-8 is virus VpZef-8, and others are named in the same manner. 099-89
Eur. 314 224; 3 May 1989 A vaccine for protecting poultry from Escherichia coli septicemia comprises fimbriae of the F-11 type or an immunogenic section of the fimbriae or recombinant organisms (preferably bacteriri) containing genetic material which encodes the production of and optionally the secretion of the timbriae. The vaccine contains as the immunogenic section, an immunogenic fimbriae subunit protein. The vaccine contains l&lOO~g/ dose of fimbriae and preferably also contains an adjuvant and antibodies directed against limbriae of Fll type. Also new is a method for protecting poultry against E. coli septicemia, which comprises administering the new vaccine. In an example, an E. coliF11 limbriaecloneAM1727-pPIL291-13 wascultured for 16 h in brain heart infusion broth at 37°C and pH 7.4 with
New Plasmodium falciparum antigens useful for recombinant vaccine and antibody production and diagnosis Behringwerke
Eur. 315 085; 10 May 1989 The HRPII antigen of Plasmodium falciparum strain SGE2, of specified amino acid composition, and antigenically active fragments are new. Also new are: (1) fusion proteins containing the antigens; (2) DNA and RNA encoding the antigens; (3) vectors and DNA structures encoding the antigens or fusion proteins; (4) host cell containing the DNA or vectors; and (5) antibodies produced against the antigens or fusion proteins. The recombinant antigens are useful for recombinant vaccine production and for malaria diagnosis. 100-81
Vaccine, Vol. 7, December 1989
575